Lifeline Biotechnologies, Inc. (LLBO) Stock Price & Analysis
Lifeline Biotechnologies, Inc. (LLBO) — price $0.0004 (0.00%), as of the Oct 2, 2026 trading session; market cap $1.74M.
Educational signal · not a buy or sell recommendation · How to read this
Lifeline Biotechnologies, Inc. · LLBO
Lifeline Biotechnologies, Inc. is a medical technology company focused on early disease detection. Their key product is the First Warning System, a non-invasive breast tissue abnormality detection device.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.0004 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0003 – $0.0011 | |
| Market capitalisation | $1.74M | |
| Shares traded on the day | 10.0K |
Price & events
Other perspectives
Council score for Lifeline Biotechnologies (LLBO): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the LLBO film — every key number, told as a short cinematic story
~2 min · open the film
What is Lifeline Biotechnologies (LLBO), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Lifeline Biotechnologies, Inc. (LLBO) is the company analyzed here. It is led by Caren Currier. In Q2 FY2026 it reported revenue of $0 and net income of -$1,200. The market values it at $1.74M.
What do the latest results show for Lifeline Biotechnologies (LLBO)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$1,200 | -$0.0000 (diluted) |
| Q1 FY2026 | $0 | -$1,200 | -$0.0000 (diluted) |
| Q4 FY2025 | $0 | -$1,241 | -$0.0000 (diluted) |
| Q3 FY2025 | $0 | -$30,086 | -$0.0000 (diluted) |
What are the financial strengths and risks for Lifeline Biotechnologies (LLBO)?
Short answer
Trailing ratios: earnings yield -3.4%.
Lifeline Biotechnologies Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the LLBO research dossier (written Mar 16, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
What does Lifeline Biotechnologies, Inc. do?
Lifeline Biotechnologies, Inc. is a medical technology company specializing in the development and marketing of innovative diagnostic tools for early disease detection. Its primary focus is on women's health, with products like the First Warning System, a non-invasive device for detecting breast tissue abnormalities.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (11 figures)
The 11 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.0004 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T08:44:35.833Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $1.74M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T08:44:34.805Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 10.0K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$1,200 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $0.0003 – $0.0011 | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
id.ceo | Chief executive | Caren Currier | UNRECORDED | Stored company-profile observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | earnings yield -3.4% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.